Clinical inertia in type 2 diabetes is particularly pronounced for injectable agents, with delays of 6-8 years reported to move from oral agents to insulin therapy. This can be a result of many barriers at both the patient and clinician level, from perceptions of injectable agents to lack of time to provide sufficient education. Join Dr Ronald Goldenberg for a discussion of how to overcome these barriers to initiating injectable therapy.

We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.

Disclosures:

Dr Ronald Goldenberg discloses the following: 

Speakers fees, Research fees, Consultant fees: AZ, BI, Merck, Lilly, Janssen, NovoNordisk, Sanofi

All conflicts of interest have been mitigated prior to this activity.

References:

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding Statement 

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.